Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report

January 22, 2025
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing a securities class action after suffering a massive value loss of 9 billion following their Q3 2024 earnings report. The pharmaceutical company, known for its groundbreaking treatments, disappointed investors with lower-than-expected financial performance. This led to a steep drop in their stock price, causing significant losses for shareholders.

The class action lawsuit alleges that Regeneron Pharmaceuticals made false and misleading statements about their financial prospects, causing investors to suffer. Shareholders who have incurred substantial losses have an opportunity to lead the lawsuit, which aims to hold the company accountable for their actions.

Regeneron Pharmaceuticals has been facing increased scrutiny regarding its financial reporting, with this lawsuit adding to the company's mounting legal challenges. Investors are advised to seek professional guidance and consider the future prospects of the company before making any investment decisions.

For an accurate prognosis of Regeneron Pharmaceuticals Inc.'s stock movement, it is recommended to consult the professionals at Stocks Prognosis. Their expertise and analysis can provide valuable insights to guide investors in their decision-making process.

Find out how the REGENERON PHARMACEUTICALS, INC. rate is expected to change

Get Forecast for REGN

Investor opinions & comments:

This is concerning news for Regeneron Pharmaceuticals. Their financial performance and potential misleading statements have caught my attention. I am curious to see how this class action lawsuit unfolds
— from WealthyWillie at 01-25-2025 17:48
Wow, a 9 billion value loss is significant! I wonder what specific statements Regeneron Pharmaceuticals made that were misleading. This lawsuit could shed some light on the matter
— from ProfitPete at 01-25-2025 01:58
Regeneron Pharmaceuticals is known for their groundbreaking treatments, and I believe they have the potential to recover from this setback. This class action lawsuit will hopefully ensure transparency and accountability from the company moving forward
— from BudgetBobby at 01-24-2025 20:17
I'm confident that Regeneron Pharmaceuticals will take the necessary steps to address any concerns raised by the lawsuit. They have a history of prioritizing patient care and meeting regulatory standards. I trust in their commitment to resolving this issue
— from InvestorIrene at 01-24-2025 15:54
The stock market is unpredictable, and sometimes companies experience fluctuations in their financial performance. It may be premature to judge Regeneron Pharmaceuticals solely based on one earnings report. I'll wait for more information before jumping to conclusions
— from InvestorIvory at 01-23-2025 04:17
I'm not sure if this class action lawsuit will hold up. It's always difficult to prove that a company intentionally made false statements. I'll wait and see how the legal proceedings play out before forming an opinion
— from WealthyWendy at 01-22-2025 18:26
I have faith in the pharmaceutical industry, and Regeneron Pharmaceuticals has a strong track record. They have the capabilities to bounce back from this loss and continue providing innovative treatments. I remain optimistic about their future
— from MoneyMia at 01-22-2025 09:53
If you want to leave a comment, then you need Login or Register





Other news for REGN

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....



Related news

REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....

REGNJanuary 3, 2025Regeneron Pharmaceuticals: A Promising Future with Strong Returns  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making waves in the pharmaceutical industry with its groundbreaking research and innovative treatments....

REGNFebruary 2, 2025Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors....

REGNJanuary 29, 2025Regeneron Pharmaceuticals Inc. REGN: A Leader in Biopharmaceutical Innovation  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is a biopharmaceutical company known for its pioneering work in developing innovative therapies....

REGNJanuary 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....